Aortic Valve Stenosis Clinical Trial
Official title:
Left Ventricular Reverse Remodeling in Aortic Valve Replacement With Single Strip Pericardium and Mechanical Valve: A Comparative Study
Aortic stenosis is a commonly found heart disease, which often leads to mortality and
morbidity. Valve replacement using mechanical prosthetic valve will have an expensive cost
especially in the Integrated Heart Center of Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
In addition to the expensive cost, patients who have mechanical prosthetic valve have an
increased risk of infection of the prosthetic valve and developing thrombo-embolism thus have
to consume a lifelong anticoagulant therapy that increase risk of bleeding. A surgical
technique using autologous pericardium is an alternative to prosthetic valve replacement, one
of which is a single pericardium strip technique that uses modified autologous pericardium
technique from Ozaki et al and Duran et al.
The objective of this study is to investigate the outcome of aortic valve replacement with a
single pericardium strip of autologous pericardium in patients with aortic stenosis.
This study will be conducted at the Integrated Heart Center of Cipto Mangunkusumo Hospital,
Jakarta, Indonesia, by using quasi experimental type time series design. Subjects are
patients with aortic stenosis who are candidates for valve replacement. Inclusion criteria is
having low to moderate surgical risk (EuroScore II <5). The sampling method used in this
study is non-probability consecutive sampling. This study will assess the outcome of the
aortic valve replacement (valve hemodynamic, left ventricular reverse remodelling, sST2,
6MWT) at 3 months and 6 months post-aortic valve replacement.
It is expected that aortic valve replacement using a single strip of autologous pericardium
will have good valve hemodynamic outcome, yield left ventricular reverse remodelling,
decrease sST2 level, show upgrade in 6MWT, and have shorter aortic cross clamp time so that
it can be an alternative to aortic valve replacement using mechanical prosthetic valve that
is less expensive and have good outcomes in patient with aortic stenosis.
Status | Recruiting |
Enrollment | 62 |
Est. completion date | April 20, 2020 |
Est. primary completion date | January 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged more than 10 years old - Patients with aortic valve stenosis with an indication of aortic valve replacement having low to moderate surgical risk (EuroScore II <5) - The patient or guardian (the research subject's parent) agrees to follow the study Exclusion Criteria: - Patients who have previously underwent aortic valve replacement - Patients with aortic stenosis due to bicuspid aortic valve - Patients with autoimmune disease - Patients with mixed connective tissue disease |
Country | Name | City | State |
---|---|---|---|
Indonesia | Cipto Mangunkusumo Central National Hospital | Jakarta | DKI Jakarta |
Lead Sponsor | Collaborator |
---|---|
Fakultas Kedokteran Universitas Indonesia |
Indonesia,
Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart. 2016 Jan;102(1):75-85. doi: 10.1136/heartjnl-2014-307020. Epub 2015 Nov 5. Review. — View Citation
d'Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B. Valvular heart disease: the next cardiac epidemic. Heart. 2011 Jan;97(2):91-3. doi: 10.1136/hrt.2010.205096. Epub 2010 Dec 13. Erratum in: Heart. 2011 Jul;97(13):1112. — View Citation
Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010 May;85(5):483-500. doi: 10.4065/mcp.2009.0706. Review. — View Citation
Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Duration of Intensive Care Unit Stay | Number of hours in the Intensive Care Unit since after the surgery until subject is transferred to hospital ward | at the time of surgery | |
Other | Duration of Ventilator Use | Number of hours of breathing assisted with ventilator since intubation until extubation | at the time of surgery | |
Primary | Change in Left Ventricular End Diastolic Diameter | Left Ventricular End Diastolic Diameter in mili meters assessed by Trans-thoracic Echocardiography measurement on M-mode | before surgery, 3 months and 6 months after surgery | |
Primary | Change in Left Ventricular End Systolic Diameter | Left Ventricular End Systolic Diameter in mili meters assessed by Trans-thoracic Echocardiography measurement on M-mode | before surgery, 3 months and 6 months after surgery | |
Primary | Change in Ejection Fraction Percentage | Ejection Fraction Percentage assessed by Trans-thoracic Echocardiography with modified Simpson's volumetric method (BiPlane measurement: apical 4 chambers and apical 2 chambers) | before surgery, 3 months and 6 months after surgery | |
Primary | Change in 6 Minute Walking Test Performance (meters) | Subjects will be asked to walk for six minutes on a given track then the distance achieved will be measured in meters | before surgery, 3 months and 6 months after surgery | |
Primary | Change in 6 Minute Walking Test Performance (METs) | The result of distance in meters of the six minute walking test will be converted to VO2max by the given formula: (distance in meters x 0.03) + 3.98 = VO2max Then the VO2max will be converted to METs by given formula: VO2max : 3.5 = METs |
before surgery, 3 months and 6 months after surgery | |
Primary | Change in Soluble Suppression of Tumorigenicity-2 (sST2) Level | Level of soluble Suppression of Tumorigenicity-2 measured in nano gram per mili Liters (ng/mL) by quantitative sandwich enzyme immunoassay technique assessed with Quantikinine Elisa | before surgery, 3 months and 6 months after surgery | |
Secondary | Coaptation Height of Aortic Valve Leaflet in mili meters | Aortic Valve Coaptation height measured in mili meters by Trans-oesophageal Echocardiography on mid-oesophageal long axis view | at the time of surgery | |
Secondary | Effective Height of Aortic Valve in mili meters | Effective Height of Aortic Valve measured in mili meters from Aortic annulus to the highest point of Aortic Valve coaptation by Trans-oesophageal Echocardiography in mid-oesophageal long axis view | at the time of surgery | |
Secondary | Aortic Jet Velocity Value in m/s | Aortic Jet Velocity value measured in meters per second (m/s) by Color Wave Doppler on Trans-thoracic Echocardiography | before surgery | |
Secondary | Mean Trans-aortic Pressure Gradient Value in mmHg | Mean Trans-aortic Pressure Gradient Value measured in mili meters Hydrargyrum (mmHg) with Bernoulli equation on Trans-thoracic Echocardiography | before surgery | |
Secondary | Aortic Stenosis Severity | Aortic Stenosis Severity classified as mild, moderate, and severe based on Recommendations from European Association of Echocardiography and American Society of Echocardiography (EAE/ASE) | before surgery | |
Secondary | Aortic Regurgitation Severity | Aortic Regurgitation Severity classified as mild, moderate, and severe based on Recommendations from American Society of Echocardiography | before surgery | |
Secondary | Number of Valve Replacement and/or Repair | Number of valves being replaced and/or repaired | at the time of surgery | |
Secondary | Aortic Cross Clamp Time in minute | The time from Aortic Cross Clamp On to Cross Clamp Off | at the time of surgery | |
Secondary | Surgery Time in minute | The time from first incision to finished closing surgical wound | at the time of surgery | |
Secondary | Cardiopulmonary Bypass Time in minute | The time from begin Cardiopulmonary Bypass (CPB) On to CPB Off | at the time of surgery | |
Secondary | Duration of Hospitalization | Number of days of Hospitalization since admission date to discharge date | at the time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|